Streamlined rAAV HeLaS3 producer cell line generation via GS selection

1. Zwi-Dantsis, L., Mohamed, S., Massaro, G. & Moeendarbary, E. Adeno-associated virus vectors: principles, practices, and prospects in gene therapy. Viruses 17(2), 239; https://doi.org/10.3390/v17020239 (2025).

   Google Scholar 

2. Liu, Z. et al. The clinical safety landscape for ocular AAV gene therapies: a systematic review and meta-analysis. iScience 28, 112265; https://doi.org/10.1016/j.isci.2025.112265 (2025).

   Google Scholar 

3. Reid, C. A., Hörer, M. & Mandegar, M. A. Advancing AAV production with high-throughput screening and transcriptomics. Cell Gene. Ther. Insights 10, 821–840;  https://doi.org/10.18609/CGTI.2024.095 (2024).

   Google Scholar 

4. Merten, O.-W. Development of stable packaging and producer cell lines for the production of AAV vectors. Microorganisms 12, 384; https://doi.org/10.3390/microorganisms12020384 (2024).

   Google Scholar 

5. Escandell, J. M. et al. Leveraging rAAV bioprocess understanding and next generation bioanalytics development. Curr. Opin. Biotechnol. 74, 271–277; https://doi.org/10.1016/j.copbio.2021.12.009 (2022).

   Google Scholar 

6. Clark, K. R., Voulgaropoulou, F., Fraley, D. M. & Johnson, P. R. Cell lines for the production of recombinant adeno-associated virus. Hum. Gene. Ther. 6, 1329–1341; https://doi.org/10.1089/hum.1995.6.10-1329 (1995).

   Google Scholar 

7. Escandell, J. et al. Towards a scalable bioprocess for rAAV production using a HeLa stable cell line. Biotechnol. Bioeng. 120, 2578–2587; https://doi.org/10.1002/bit.28394 (2023).

   Google Scholar 

8. Martin, J. et al. Generation and characterization of adeno-associated virus producer cell lines for research and preclinical vector production. Hum. Gene. Ther. Methods 24, 253–269; https://doi.org/10.1089/hgtb.2013.046 (2013).

   Google Scholar 

9. Escandell, J. M. et al. Development of a serum-free producer cell line generation process for scalable and efficient rAAV production for gene therapy applications. bioRxiv. https://doi.org/10.1101/2025.10.02.679972 (2025).

10. Yu, D. Y., Lee, S. Y. & Lee, G. M. Glutamine synthetase gene knockout-human embryonic kidney 293E cells for stable production of monoclonal antibodies. Biotechnol. Bioeng. 115, 1367–1372; https://doi.org/10.1002/bit.26552 (2018).

    Google Scholar 

11. Chin, C. L. et al. A human expression system based on HEK293 for the stable production of recombinant erythropoietin. Sci. Rep. 9, 16768; https://doi.org/10.1038/s41598-019-53391-z (2019).

    Google Scholar 

12. Fan, L., Frye, C. C. & Racher, A. J. The use of glutamine synthetase as a selection marker: recent advances in Chinese hamster ovary cell line generation processes. Pharm. Bioprocess 1, 487–502; https://doi.org/10.4155/PBP.13.56 (2013).

    Google Scholar 

13. Srivastava, A., Mallela, K. M. G., Deorkar, N. & Brophy, G. Manufacturing challenges and rational formulation development for AAV viral vectors. J. Pharm. Sci. 110, 2609–2624; https://doi.org/10.1016/j.xphs.2021.03.024 (2021).

    Google Scholar 

14. Xue, W. et al. Adeno-associated virus perfusion enhanced expression: a commercially scalable, high titer, high quality producer cell line process. Mol. Ther. Methods Clin. Dev. 32, 101266; https://doi.org/10.1016/j.omtm.2024.101266 (2024).

    Google Scholar 

15. Prasad, A. et al. Low-dose exposure to phytosynthesized gold nanoparticles combined with glutamine deprivation enhances cell death in the cancer cell line HeLa via oxidative stress-mediated mitochondrial dysfunction and G0/G1 cell cycle arrest. Nanoscale 14, 10399–10417; https://doi.org/10.1039/D2NR02150A (2022).

    Google Scholar 

16. Reitzer, L. J., Wice, B. M. & Kennell, D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J. Biol. Chem. 254, 2669–76 (1979).

    Google Scholar 

17. Srila, W. et al. Glutamine synthetase (GS) knockout (KO) using CRISPR/Cpf1 diversely enhances selection efficiency of CHO cells expressing therapeutic antibodies. Sci. Rep. 13, 10473; https://doi.org/10.1038/s41598-023-37288-6 (2023).

    Google Scholar 

18. Fu, Q., Polanco, A., Lee, Y. S. & Yoon, S. Critical challenges and advances in recombinant adeno-associated virus (rAAV) biomanufacturing. Biotechnol. Bioeng. 120, 2601–2621; https://doi.org/10.1002/bit.28412 (2023).

    Google Scholar 

19. Destro, F. et al. The state of technological advancement to address challenges in the manufacture of rAAV gene therapies. Biotechnol. Adv. https://doi.org/10.1016/j.biotechadv.2024.108433 (2024).

    Google Scholar 

20. Lorek, J. K., Isaksson, M. & Nilsson, B. Chromatography in downstream processing of recombinant adeno-associated viruses: a review of current and future practises. Biotechnol. Bioeng. https://doi.org/10.1002/bit.28932 (2025).

    Google Scholar 

21. FDA. Manufacturing changes and comparability for human cellular and gene therapy products; draft guidance for industry. http://www.regulations.gov. (2023).

22. Fernandes, S., Guerra, J., Ferreira, M. V. & Coroadinha, A. S. Deciphering key adenoviral elements in the production of recombinant adeno-associated virus vectors. Hum Gene Ther 36; https://doi.org/10.1089/hum.2024.265 (2025).

Download references

Authors and Affiliations

1. iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, Oeiras, 2781-901, Portugal

   Mariana Antunes, Filipa Moura, Paula Alves, Patrícia Gomes-Alves & Jose M. Escandell

2. Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Av. da República, Oeiras, 2780-157, Portugal

   Mariana Antunes, Filipa Moura, Paula Alves, Patrícia Gomes-Alves & Jose M. Escandell

3. Department of Biotechnology and Food Science, BOKU University, Institute of Animal Cell Technology and Systems Biology, Muthgasse 11, Vienna, 1190, Austria

   Ivy Rose Sebastian

Contributions

M.A writing – original draft, investigation, methodology, visualization, and formal analysis. F.M., investigation, methodology, visualization, and formal analysis. I.R.S investigation, methodology, and formal analysis. P.M.A, supervision and funding acquisition P.G.A. supervision, project supervision, project administration, funding acquisition. J.M.E., writing – original draft, project conceptualization, supervision, project supervision, investigation, funding acquisition. All authors: writing – review & editing.

Corresponding author

Correspondence to Jose M. Escandell.

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions